Trial shows prophylactic nasal spray prevents SARS-CoV-2 infection

Oct. 1, 2021

pHOXBIO announced results from a randomized, double-blind, placebo-controlled clinical trial showing that pHOXWELL, its prophylactic nasal spray, prevented infection from SARS-CoV-2, the virus that causes COVID-19.

In a Phase 2/3 clinical study, there were 63% fewer SARS-CoV-2 infections in high-risk healthcare workers given pHOXWELL compared to placebo.

pHOXWELL is a self-administered prophylactic nasal spray designed to offer a variant-agnostic mechanism of action that inhibits the infection processes of SARS-CoV-2. It is designed to be effective against other airborne respiratory viruses. The product offers 6-8 hours of protection with just two sprays per nostril, per application.

The study was a double-blind, randomized, placebo-controlled study to assess the efficacy and safety of the pHOXWELL nasal spray in the prevention of SARS-CoV-2 infection in high-risk healthcare professionals in India. The trial was carried out during the peak surge of the highly infectious Delta variant in India from April to July 2021.

Visit pHOXBIO for more news